| abstract |
The present invention relates to a medicament intended for the treatment of a disease state in which the number of antigen sites or antigen density is low, a disease state in which an antibody is relatively inaccessible to an antigen, or a disease state in which the number of activated or recruited effector cells is small. Of optimized human or humanized chimeric monoclonal antibodies for the preparation of products. Produced in a cell line selected by the glycosylation properties of the Fc fragment of the antibody, or b) the glycan structure of Fcγ is modified ex vivo, and / or c) with the Fc receptor A chimeric monoclonal antibody whose primary sequence has been modified to increase reactivity. [Selection figure] None |